Nisa Investment Advisors LLC Buys 927 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Nisa Investment Advisors LLC raised its position in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 38.4% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 3,340 shares of the company’s stock after purchasing an additional 927 shares during the period. Nisa Investment Advisors LLC’s holdings in IDEAYA Biosciences were worth $117,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also bought and sold shares of the company. SG Americas Securities LLC boosted its position in IDEAYA Biosciences by 411.3% during the second quarter. SG Americas Securities LLC now owns 11,775 shares of the company’s stock worth $413,000 after purchasing an additional 9,472 shares during the period. Boston Partners purchased a new position in IDEAYA Biosciences during the first quarter worth about $588,000. Farallon Capital Management LLC bought a new position in shares of IDEAYA Biosciences in the 1st quarter worth $219,000. Comerica Bank raised its holdings in shares of IDEAYA Biosciences by 723.5% during the 1st quarter. Comerica Bank now owns 1,507 shares of the company’s stock valued at $66,000 after buying an additional 1,324 shares in the last quarter. Finally, California State Teachers Retirement System boosted its stake in shares of IDEAYA Biosciences by 19.0% in the 1st quarter. California State Teachers Retirement System now owns 57,535 shares of the company’s stock valued at $2,525,000 after purchasing an additional 9,176 shares in the last quarter. 98.29% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

IDYA has been the subject of a number of recent analyst reports. Mizuho initiated coverage on shares of IDEAYA Biosciences in a report on Monday, July 8th. They set an “outperform” rating and a $50.00 price target for the company. Stifel Nicolaus restated a “buy” rating and set a $63.00 price target on shares of IDEAYA Biosciences in a report on Monday, July 8th. Lifesci Capital upgraded IDEAYA Biosciences to a “strong-buy” rating in a report on Monday, July 29th. The Goldman Sachs Group reduced their target price on IDEAYA Biosciences from $53.00 to $46.00 and set a “buy” rating on the stock in a research note on Monday, May 13th. Finally, JPMorgan Chase & Co. lowered their price objective on shares of IDEAYA Biosciences from $69.00 to $66.00 and set an “overweight” rating for the company in a report on Thursday, August 8th. Twelve equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $55.90.

IDEAYA Biosciences Stock Performance

Shares of IDYA stock opened at $39.49 on Monday. The company has a market capitalization of $2.99 billion, a price-to-earnings ratio of -19.65 and a beta of 0.87. IDEAYA Biosciences, Inc. has a one year low of $23.41 and a one year high of $47.74. The company’s 50-day moving average is $38.53 and its 200 day moving average is $40.83.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its quarterly earnings data on Tuesday, August 6th. The company reported ($0.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.14). IDEAYA Biosciences had a negative return on equity of 20.09% and a negative net margin of 483.05%. During the same quarter in the previous year, the business earned ($0.50) earnings per share. As a group, research analysts predict that IDEAYA Biosciences, Inc. will post -2.22 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Michael Anthony White sold 28,500 shares of IDEAYA Biosciences stock in a transaction dated Wednesday, May 29th. The stock was sold at an average price of $36.24, for a total value of $1,032,840.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 3.50% of the company’s stock.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.